

Sabine Vogler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504819/publications.pdf>

Version: 2024-02-01

65
papers

1,822
citations

304602

22
h-index

276775

41
g-index

67
all docs

67
docs citations

67
times ranked

1731
citing authors

#	ARTICLE	IF	CITATIONS
1	Purchasing medicines for the public sector: Evaluation of the performance of centralised procurement in Portugal. <i>International Journal of Health Planning and Management</i> , 2022, 37, 2007-2031.	0.7	3
2	Pharmaceutical regulation and policies in Austria. <i>Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde</i> , 2022, 13, 639.	0.0	2
3	"Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.. <i>GMS German Medical Science</i> , 2022, 20, Doc05.	2.7	1
4	Centralised Pharmaceutical Procurement: Learnings from Six European Countries. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 637-650.	1.0	7
5	Can we achieve affordable cancer medicine prices? Developing a pathway for change. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 321-325.	0.7	9
6	Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. <i>Frontiers in Pharmacology</i> , 2021, 12, 625296.	1.6	41
7	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 18.	1.1	5
8	Preisregulierungen im internationalen Vergleich. , 2021, , 125-138.		1
9	European collaborations on medicine and vaccine procurement. <i>Bulletin of the World Health Organization</i> , 2021, 99, 715-721.	1.5	10
10	Biologika und Biosimilars in Deutschland und im europäischen Vergleich – Marktsteuerungsmechanismen und Preisvergleich. , 2021, , 75-107.		3
11	Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 51.	0.6	4
12	How to address medicines shortages: Findings from a cross-sectional study of 24 countries. <i>Health Policy</i> , 2020, 124, 1287-1296.	1.4	22
13	Public spending on orphan medicines: a review of the literature. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 66.	1.1	8
14	Medicines with one seller and many buyers: strategies to increase the power of the payer. <i>BMJ</i> , The, 2020, 369, m1705.	3.0	11
15	The impact of managed entry agreements on pharmaceutical prices. <i>Health Economics (United Kingdom)</i> 41 0.784314 0.8rgBT / Overlock 21		10
16	Medicines Pricing: Limitations of Existing Policies and New Models. , 2020, , 99-137.		2
17	Biosimilars in Deutschland und im europäischen Vergleich – Marktsteuerungsmechanismen und Einsparpotenziale. , 2020, , 201-225.		4
18	Fair prices for medicines? Exploring competent authorities' and public payers' preferences on pharmaceutical policies. <i>Empirica</i> , 2019, 46, 443-469.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 803-816.	1.0	9
20	Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. <i>International Journal for Equity in Health</i> , 2019, 18, 89.	1.5	5
21	Assessing Data Sources for Medicine Price Studies. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 106-115.	0.2	5
22	External Price Referencing Policy Brief. , 2019, , 433-439.		0
23	Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. <i>PharmacoEconomics - Open</i> , 2019, 3, 303-309.	0.9	20
24	Price Studies for Specific Medicines. , 2019, , 113-164.		0
25	Assessment of External Price Referencing and Alternative Policies. , 2019, , 369-419.		0
26	Review of studies reporting actual prices for medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 159-179.	0.7	14
27	Practice of External Price Referencing. , 2019, , 345-368.		3
28	Biosimilars in Deutschland und im europÃ¤ischen Vergleich â€“ Entwicklungen und Potenziale. , 2019, , 321-353.		5
29	Access to High-Cost Medicines in Europe. , 2018, , 143-164.		2
30	Marktzugang, Erstattung und Preissetzung neuer patentgeschÃ¼tzter Arzneimittel in der EuropÃ¤ischen Union. , 2018, , 239-260.		5
31	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	1.0	111
32	Payersâ€™ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. <i>Health Policy</i> , 2017, 121, 354-362.	1.4	67
33	Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 147-158.	0.3	20
34	Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. <i>PharmacoEconomics - Open</i> , 2017, 1, 145-147.	0.9	34
35	Price comparison of high-cost originator medicines in European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 221-230.	0.7	22
36	Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. <i>Frontiers in Pharmacology</i> , 2017, 8, 171.	1.6	107

#	ARTICLE	IF	CITATIONS
37	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	1.1	16
38	Policy interventions related to medicines: Survey of measures taken in European countries during 2010â€“2015. <i>Health Policy</i> , 2016, 120, 1363-1377.	1.4	28
39	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.	3.1	9
40	Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002032.	3.9	198
41	Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement. <i>Health Policy and Technology</i> , 2016, 5, 213-225.	1.3	8
42	Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. <i>Lancet Oncology</i> , The, 2016, 17, 39-47.	5.1	137
43	Policy options to deal with high-cost medicines â€“ survey with European policy-makers. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	1.1	4
44	The Pharmaceutical Pricing and Reimbursement Information (PPRI) network â€“ a decade of exchange of information and policy research?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	1.1	6
45	Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. <i>International Journal for Equity in Health</i> , 2015, 14, 124.	1.5	22
46	Analysis of Medicine Prices in New Zealand and 16 European Countries. <i>Value in Health</i> , 2015, 18, 484-492.	0.1	40
47	Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. <i>International Journal for Equity in Health</i> , 2014, 13, 53.	1.5	25
48	Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. <i>Bulletin of the World Health Organization</i> , 2014, 92, 630-640D.	1.5	39
49	Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 6.	1.1	33
50	The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiativeâ€”Experiences from engaging with pharmaceutical policy makers. <i>Health Policy and Technology</i> , 2014, 3, 139-148.	1.3	34
51	Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. <i>Health Policy</i> , 2014, 117, 311-327.	1.4	38
52	The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 15.	0.6	19
53	Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 73-78.	0.8	74
54	Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. <i>Health Policy</i> , 2013, 112, 209-216.	1.4	29

#	ARTICLE	IF	CITATIONS
55	Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. <i>The Open Pharmacoeconomics & Health Economics Journal</i> , 2013, 5, 1-10.	0.6	16
56	Understanding the components of pharmaceutical expenditure – overview of pharmaceutical policies influencing expenditure across European countries. <i>GaBI Journal</i> , 2013, 2, 178-187.	0.4	12
57	Differences in external price referencing in Europe – A descriptive overview. <i>Health Policy</i> , 2012, 104, 50-60.	1.4	97
58	The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. <i>GaBI Journal</i> , 2012, 1, 93-100.	0.4	77
59	How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. <i>Farmeconomia E Percorsi Terapeutici</i> , 2012, 13, 29-41.	0.2	17
60	Discounts and rebates granted to public payers for medicines in European countries. <i>Southern Med Review</i> , 2012, 5, 38-46.	0.8	49
61	Impact of external price referencing on medicine prices - a price comparison among 14 European countries. <i>Southern Med Review</i> , 2012, 5, 34-41.	0.8	30
62	Pharmaceutical policies in European countries in response to the global financial crisis. <i>Southern Med Review</i> , 2011, 4, 69-79.	0.8	101
63	Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. <i>Croatian Medical Journal</i> , 2011, 52, 183-197.	0.2	48
64	Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain. <i>Pharmaceuticals Policy and Law</i> , 2009, 11, 213-234.	0.1	20
65	Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 114-119.	0.2	1